Clinical trials: in Germany
Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.
- Trial name
- ENERGIZE-T (NCT04770779)
- Testing
- Mitapivat
- Where
- 75 sites in United States, Brazil and 17 more
- Volunteers
- 258 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Head and Neck Squamous Cell Carcinoma
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer.
- Trial name
- NCT06806852
- Testing
- BI 770371, Pembrolizumab, Cetuximab
- Where
- 51 sites in United States, Australia and 20 more
- Volunteers
- 91 people
- Sponsor
- Boehringer Ingelheim
Cancer
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with…
- Trial name
- DARO ROLL OVER (NCT04464226)
- Testing
- Darolutamide (Nubeqa, BAY1841788)
- Where
- 335 sites in United States, Argentina and 37 more
- Volunteers
- 774 people
- Sponsor
- Bayer
Niemann-Pick Type C Disease
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease
- Trial name
- NCT07082725
- Testing
- Nizubaglustat
- Where
- 34 sites in United States, Argentina and 13 more
- Volunteers
- 72 people
- Sponsor
- Azafaros B.V.
Migraine
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.
- Trial name
- AURORA (NCT06602479)
- Testing
- MEDI0618
- Where
- 71 sites in United States, Czechia and 6 more
- Volunteers
- 309 people
- Sponsor
- AbbVie
Pyruvate Kinase Deficiency
Pyruvate Kinase Deficiency Global Longitudinal Registry
This study is an observational (ie, noninterventional), longitudinal, multicenter, global registry for patients with pyruvate kinase (PK) deficiency, a rare nonspherocytic hemolytic anemia.
- Trial name
- PEAK Registry (NCT03481738)
- Where
- 52 sites in United States, Canada and 14 more
- Volunteers
- 500 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Hepatic Encephalopathy
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE)…
- Trial name
- RED-C-3132 (NCT05297448)
- Testing
- Rifaximin SSD
- Where
- 188 sites in United States, Australia and 15 more
- Volunteers
- 517 people
- Sponsor
- Bausch Health Americas, Inc.
Migraine
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine.
- Trial name
- OASIS(CM) (NCT03832998)
- Testing
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3
- Where
- 101 sites in United States, Belgium and 11 more
- Volunteers
- 284 people
- Sponsor
- Amgen
Colorectal Cancer, Pancreatic Cancer
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when…
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
- Trial name
- NCT04421820
- Testing
- BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 220 people
- Sponsor
- Bold Therapeutics, Inc.
Proteinuric Kidney Diseases
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFSGS), treatment-resistant primary minimal change disease (TR-pMCD), Alport Syndrome (AS), and…
- Trial name
- NCT07355296
- Testing
- BI 764198
- Where
- 154 sites in United States, Argentina and 30 more
- Volunteers
- 132 people
- Sponsor
- Boehringer Ingelheim
Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe.
- Conditions
- Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
- Trial name
- NCT07201922
- Testing
- Nerandomilast
- Where
- 55 sites in United States, Argentina and 11 more
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Hypertension
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.
- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
- Trial name
- NCT07064473
- Testing
- Vicadrostat, Empagliflozin
- Where
- 1,142 sites in United States, Argentina and 49 more
- Volunteers
- 11,800 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
An observational study to describe the effectiveness, safety, and patient-reported outcomes in patients with moderate to severe active rheumatoid arthritis (RA) receiving filgotinib in real-world setting.
- Trial name
- FILOSOPHY (NCT04871919)
- Testing
- Filgotinib
- Where
- 89 sites in Belgium, Germany and 4 more
- Volunteers
- 1,304 people
- Sponsor
- Alfasigma S.p.A.
Carcinoma, Non-Small-Cell Lung
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788…
- Trial name
- NCT02716116
- Testing
- TAK-788
- Where
- 62 sites in United States, China and 8 more
- Volunteers
- 324 people
- Sponsor
- Takeda
Recurrent Pericarditis, Heart Diseases
Transition to KPL-387 Monotherapy Dosing & Administration Study
The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent…
- Conditions
- Recurrent Pericarditis, Heart Diseases, Pericarditis
- Trial name
- NCT07288216
- Testing
- KPL-387
- Where
- 48 sites in United States, Canada and 8 more
- Volunteers
- 120 people
- Sponsor
- Kiniksa Pharmaceuticals International, plc
Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study.
- Trial name
- NCT06806592
- Testing
- Nerandomilast
- Where
- 153 sites in United States, Australia and 14 more
- Volunteers
- 414 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with…
- Trial name
- NCT07217067
- Testing
- PKN605
- Where
- 40 sites in United States, Canada and 5 more
- Volunteers
- 165 people
- Sponsor
- Novartis Pharmaceuticals
Biliary Tract Cancer
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice…
- Trial name
- NCT06282575
- Testing
- Zanidatamab, Cisplatin, Gemcitabine
- Where
- 185 sites in United States, Argentina and 23 more
- Volunteers
- 286 people
- Sponsor
- Jazz Pharmaceuticals
Advanced or Metastatic Non-small Cell Lung Cancer
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
- Trial name
- ALTAIR (NCT06996782)
- Testing
- Rilvegostomig, Cisplatin, Carboplatin
- Where
- 103 sites in United States, Belgium and 18 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies
- Conditions
- Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
- Trial name
- Soundtrack-E (NCT06564038)
- Testing
- Surovatamig, Prednisone (or equivalent), Rituximab
- Where
- 66 sites in United States, Australia and 11 more
- Volunteers
- 408 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.